Is Private Healthcare Still An Interesting Asset Class?

Suchira Sharma
Jul 31
Updated: Aug 1

In the current interest-rate environment, many investors have been re-thinking their asset allocation strategies in order to meet or maximize their annual return targets. With many potential asset classes and sectors vying for investors’ allocation, we continue to believe that private healthcare investing is a conservative strategy during market volatility, with a potential for outsized performance and asymmetric return.

Why Invest in Healthcare as a subsector?

Healthcare has long been considered a “defensive growth” sector, given that that there has historically been limited correlation with global macroeconomic conditions – demand for healthcare is traditional stable and there is limited impact from swings in the economy. This is further supported by growing demographic trends as populations age and the wealth of the middle class rises.

Public healthcare stocks have also outperformed the broader market during the past three recessionary cycles:

We saw a glimmer of this last year as well: In 2022, the S&P 500’s healthcare sector index was down <10%, on pace for its worst year since 2008. Yet it has still outperformed the broader market by >10 percentage points, the widest gap since 2000, according to Dow Jones Market Data.

Why Invest in Healthcare Private Equity?

While healthcare will continue to be a strong and stable sector for investment, we believe investing in private healthcare companies in particular can meaningfully drive alpha in investor portfolios.

In reviewing private equity data from the past two recessions, it is clear that investing in private healthcare is “recession-proof” and outperforms public equities on a risk-adjusted basis: the median IRR for healthcare PE following the dot-com recession was 45% (vs. 30% IRR of the broader PE market). Two years following the 2008 recession, IRRs for healthcare PE were 22%, in-line with the broader PE market, and outperforming the S&P index (15% annual return):

In addition, healthcare Private Equity tends to offer an evergreen source of deal opportunities since innovation is constant due to macro-level tailwinds. Healthcare consistently represents ~20% of US GDP. Factors such as a growing aging population, people living longer with chronic diseases, the obesity and diabetes epidemics, the global reach of diseases, and the growing adaptation to personalized medicines, not only create stable demand for the industry but drive constant transformation of the healthcare system. The speed of this innovation is also accelerating as we learn more about human biology, and leverage technologies from other industries. All of these factors create multiple diversified opportunities for investment in the private markets.

In conclusion, investors have many opportunities today to diversify their holdings and maximize their asset allocation strategies in order to drive alpha. We continue to believe that investing in private healthcare companies is an attractive opportunity given (1) macro-level tailwinds affecting the sector, (2) outperformance of the sector relative to the broader market, especially in recessionary periods, and (3) outperformance of healthcare private equity in particular, relative to the broader market. For more information on our Revelation’s approach for investing in private healthcare companies, please visit https://www.revelation-partners.com/our-focus.

Disclaimer

The information contained herein is for informational and educational purposes only, does not constitute an offer to sell or the solicitation of an offer to purchase any security, is not presented with a view to providing investment advice with respect to any security, or making any claim as to the past, current or future performance thereof, and Revelation expressly disclaims the use of this document for such purposes. Each recipient should consult its own advisers as to legal, business, tax and other related matters concerning any investment.

Statements contained herein are based on current expectations, estimates, projections, opinions, views and beliefs of Revelation as of the date of this document. Such statements involve known and unknown risks and uncertainties, and undue reliance should not be placed thereon. Neither Revelation nor any of its affiliates makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein and nothing contained herein should be relied upon as a promise or representation as to past or future performance. Revelation and its members, partners, stockholders, managers, directors, officers, employees and agents do not have any obligation to update any information included herein. Certain information contained herein has been obtained from published and non-published sources and/or prepared by third-parties, and in certain cases has not been updated through the date hereof. While such information is believed to be reliable for the purposes of this document, Revelation assumes no responsibility for the accuracy or completeness of such information and such information has not been independently verified by it. The inclusion of any third-party firm and/or company names, brands and/or logos does not imply any affiliation with these firms or companies. None of these firms or companies have endorsed Revelation or any affiliated entities or personnel. Recipients of this document agree that none of Revelation or its affiliates or its or their respective partners, members, employees, officers, directors, agents, or representatives shall have any liability for any misstatement or omission of fact or any opinion expressed herein.

Certain information contained herein constitutes “forward-looking statements,” which can be identified by the use of terms such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “projects,” “future,” “targets,” “intends,” “plans,” “believes,” “estimates” (or the negatives thereof) or other variations thereon or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, some of which are beyond the control of Revelation. Actual results, performance, prospects or opportunities could differ materially from those expressed in or implied by the forward-looking statements. Additional risks of which Revelation is not currently aware also could cause actual results to differ. In light of these risks, uncertainties and assumptions, recipients should not place undue reliance on any forward-looking statements. The forward-looking events discussed in this document may not occur. Revelation undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The delivery of this document at any time shall not under any circumstances create an implication that the information contained herein is correct as of any time after the earlier of the relevant date specified herein or the date of this document.

Any offer, sale or solicitation of interests in any private investment vehicle offered by Revelation in the future (each, a “Fund”) will be made only pursuant to such Fund’s confidential private placement memorandum (the “Memorandum”), limited partnership agreement and subscription agreement, and will be subject to the terms and conditions contained in such documents in accordance with applicable securities laws. This document is qualified in its entirety by reference to any such Fund’s Memorandum, including without limitation all of the cautionary statements and risk factors set forth therein, the applicable limited partnership agreement and the applicable subscription agreement related thereto, copies of all of which can be made available in the future to qualified investors upon request and should be read carefully prior to any investment in any such Fund.